Patient comfort assessment of the Femflow. A follow-up study of the validation of a new catheter for intermittent Self-Catheterization in female patients
- Conditions
- Acontractile or underactive bladder dysfunction: inability to empty the bladder10004994
- Registration Number
- NL-OMON45287
- Lead Sponsor
- ovuqare BV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
- Age 18-80 years
- Woman on CIC who cannot empty the bladder themselves (so no incomplete voiders)
- Patient has signed a written Informed Consent form
- Patient is free of uncontrolled psychiatric illness
- Patient is free of urinary tract infection
- is the patient free of urethral strictures, trauma of necrosis?
- Patients with large deviations in urethra or bladder caused by anatomical defects, earlier surgery or caused by other damage of the pelvic floor.
- Patients with a urinary tract infection, or a history of urinary tract infections.
- Patients who can urinate themselves, or on partial Clean Intermittent Catheterization
- Morbid obesity (BMI > 40 kg/m2)
- Patients with hematuria and/or blood clots in the urine
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Comfort during insertion - quantitative assessment by participant<br /><br>Comfort of FemFlow the bladder - quantitative assessment by participant<br /><br>Comfort during urinating - quantitative assessment by participant<br /><br>Comfort during removal of FemFlow - quantitative assessment by participant<br /><br>Comfort of FemFlow for several body postures - quantitative assessment by<br /><br>participant<br /><br><br /><br><br /><br>The primary objectives will be rated with a questionnaire, using a 1-10 scale.<br /><br>The questions are set up to rate comfort; 1 represents *extremely<br /><br>uncomfortable* and 10 represents *extremely comfortable*. The question must<br /><br>score 6 or higher to be assessed as acceptable. The average outcome of the main<br /><br>study parameters shall score 7 or higher.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary study parameters/endpoints.<br /><br>No mucosa damage.<br /><br>Cystoscopic investigation.</p><br>